In the ongoing S1404 study (NCT01274338, n = 1673), a direct comparison of the efficacy of high-dose Intron-A and ipilimumab (anti-CTLA-4) in adjuvant therapy for patients with high-risk melanoma is being conducted. Here, CTLA4 is linked to melanoma.